Utama › Kanser Paru-paru Bukan Sel Kecil › Wilayah Columbia › Washington
Kajian klinikal Kanser Paru-paru Bukan Sel Kecil di Washington, DC
55 kajian untuk Kanser Paru-paru Bukan Sel Kecil sedang mencari peserta di lokasi dalam dan sekitar Washington (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Mengambil pesertaFasa 3
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
- dan 1 lagi
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
Mengambil pesertaKajian pemerhatian
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 2
- Local Institution - 0183, Washington D.C.
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
Mengambil pesertaFasa 3
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
A Study of PHN-012 in Patients With Advanced Solid Tumors
Mengambil pesertaFasa 1
- PHN-012-001 Site, Washington D.C.
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Mengambil pesertaFasa 2
- Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital, Washington D.C.
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Mengambil pesertaKajian pemerhatian
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 3
- Maryland Oncology Hematology, P.A., Silver Spring · 7 mi jauh
- Maryland Oncology Hematology, P.A., Bethesda · 7 mi jauh
- Maryland Oncology Hematology, P.A, Largo · 11 mi jauh
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Mengambil pesertaFasa 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer
Mengambil pesertaFasa 3
- Research Site, Silver Spring · 7 mi jauh
- Research Site, Bethesda · 7 mi jauh
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Maryland Oncology Hematology, P.A., Silver Spring · 7 mi jauh
- Maryland Oncology Hematology, P.A., Bethesda · 7 mi jauh
- Maryland Oncology Hematology, P.A., Largo · 11 mi jauh
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 2
- MedStar Georgetown University Hospital, Washington D.C.
- Washington DC VA Medical Center, Washington D.C.
- Maryland Oncology Hematology P A, Silver Spring · 7 mi jauh
A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 2
- Georgetown University, Washington D.C.
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
Mengambil pesertaFasa 3
- Washington DC Veterans Affairs Medical Center, Washington D.C.
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Mengambil pesertaFasa 2
- MedStar Georgetown University Hospital, Washington D.C.
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Sibley Memorial Hospital, Washington D.C.
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
Mengambil pesertaFasa 1
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Mengambil pesertaFasa 2/3
- MedStar Georgetown-MedStar Georgetown Transplant Institute University Hospital (MGUH), Washington D.C.
- MEDSTAR Washington Hospital Center (MedStar Health Research Institute), Washington D.C.
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Mengambil pesertaFasa 1
- Georgetown University Medical Center, Washington D.C.
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 3
- Research Site, Bethesda · 7 mi jauh
- Research Site, Bethesda · 7 mi jauh
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
Mengambil pesertaFasa 3
- George Washington University Cancer Center, Washington D.C.
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Mengambil pesertaFasa 1/2
- Georgetown University Lombardi Cancer Center, Washington D.C.
- Sibley Memorial Hospital, Washington D.C.
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Mengambil pesertaFasa 2/3
- Local Institution - 007-5476, Washington D.C.
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 2
- MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center), Washington D.C.
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Mengambil pesertaFasa 3
- Sibley Memorial Hospital, Washington D.C.
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Walter Reed National Military Medical Center, Bethesda · 7 mi jauh
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Mengambil pesertaFasa 3
- Washington Hospital Center ( Site 0037), Washington D.C.
T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer
Mengambil pesertaFasa 2
- National Institutes of Health Clinical Center, Bethesda · 7 mi jauh
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Mengambil pesertaFasa 3
- Research Site, Bethesda · 7 mi jauh
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Mengambil pesertaFasa 2
- MedStar Georgetown University Hospital, Washington D.C.
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
Mengambil pesertaFasa 1
- Sibley Memorial Hospital, Washington D.C.
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Mengambil pesertaFasa 3
- Sibley Memorial Hospital, Washington D.C.
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Mengambil pesertaFasa 1/2
- National Institutes of Health, Bethesda · 7 mi jauh
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Mengambil pesertaFasa 1/2
- Georgetown University - Lombardi Comprehensive Cancer Center, Washington D.C.
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
Mengambil pesertaFasa 1/2
- Georgetown University Medical Center, Washington D.C.
Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features
Mengambil pesertaFasa 2
- Lombardi Comprehensive Cancer Center, Georgetown University, Washington D.C.
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Mengambil pesertaFasa 1/2
- Georgetown University, Washington D.C.
Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer
Mengambil pesertaFasa 1
- Maryland Oncology Hematology, Calverton · 12 mi jauh
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Mengambil pesertaFasa 1/2
- Georgetown University Medical Center, Washington D.C.
Gilteritinib for the Treatment of ALK NSCLC
Mengambil pesertaFasa 1
- Georgetown University, Washington D.C.
Study of XB010 in Subjects With Solid Tumors
Mengambil pesertaFasa 1
- Georgetown University Medical Center, Washington D.C.
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- Kaiser Permanente - Largo Medical Center, Largo · 11 mi jauh
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Mengambil pesertaFasa 2
- USA11-0, Bethesda · 7 mi jauh
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
Mengambil pesertaFasa 3
- Georgetown University Medical Cener (GUMC), Washington D.C.
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Mengambil pesertaFasa 3
- Research Site, Washington D.C.
- Research Site, Bethesda · 7 mi jauh
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2/3
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- Kaiser Permanente - Largo Medical Center, Largo · 11 mi jauh
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Mengambil pesertaFasa 2
- Kaiser Permanente-Capitol Hill Medical Center, Washington D.C.
- Kaiser Permanente - Largo Medical Center, Largo · 11 mi jauh
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Mengambil pesertaFasa 1/2
- Sibley Memorial Hospital, Washington D.C.
Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer
Mengambil pesertaFasa 2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
- Medstar Washington Hospital Center, Washington D.C.
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Mengambil pesertaFasa 1
- National Cancer Institute, Bethesda · 7 mi jauh
Repositioning Immunotherapy in VetArans With Lung Cancer
Mengambil pesertaFasa 2
- VA Central Office, Washington, DC, Washington D.C.
GEMINI-NSCLC: NSCLC Biomarker Study
Mengambil pesertaKajian pemerhatian
- The Center for Cancer and Blood Disorder, Bethesda · 7 mi jauh
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Mengambil pesertaFasa 1/2
- The George Washington University Cancer Center (site 212), Washington D.C.
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Mengambil pesertaKajian pemerhatian
- Massive Bio SYNERGY-AI site, Silver Spring · 7 mi jauh
- Massive Bio SYNERGY-AI site, Bethesda · 7 mi jauh
FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations
Mengambil pesertaFasa 1/2
- Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Kajian Kanser Paru-paru Bukan Sel Kecil di bandar lain
- Houston, TX145 kajian
- New York City, NY121 kajian
- Arlington, VA104 kajian
- Nashville, TN97 kajian
- Boston, MA90 kajian
- Los Angeles, CA87 kajian
- St. Louis, MO73 kajian
- Chicago, IL61 kajian
- Baltimore, MD60 kajian
- San Antonio, TX59 kajian
- Columbus, OH57 kajian
- Seattle, WA53 kajian
Kajian lain di Washington
- Kanser (semua jenis)58 kajian
- Kanser Payudara46 kajian
- Kanser Metastatik43 kajian
- Kanser Paru-paru41 kajian
- Kanser Prostat38 kajian
- Obesiti33 kajian
- Kanser Kolorektal29 kajian
- Penyakit Kardiovaskular28 kajian
- Kanser Pundi Kencing26 kajian
- Leukemia Mieloid Akut24 kajian
- Kanser Ovari23 kajian
- Limfoma23 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.